Jeffrey D. Esko

Jeffrey D. Esko

Auto-generated profile, based on publicly available information

Jeffrey D. Esko

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2007 in Nature
Verified
Journal Article
Closed access
PDF file
JBJoseph R. Bishop
Joseph R. Bishop
MSManuela Schuksz
Manuela Schuksz
JEJeffrey D. Esko
Jeffrey D. Esko

20 June 2011 in Cold Spring Harbor Perspectives in Biology
Verified
Journal Article
Open access
PDF file
SSStephane Sarrazin
Stephane Sarrazin
WLWilliam C. Lamanna
William C. Lamanna
JEJeffrey D. Esko
Jeffrey D. Esko
Heparan sulfate proteoglycans are found at the cell surface and in the extracellular matrix, where they interact with a plethora of ligands. Over the last decade, new insights have emerged regarding the mechanism and biological significance of these interactions. Here, we discuss changing views on the specificity of protein–heparan sulfate binding and the activity of HSPGs as receptors and coreceptors. Although few in number, heparan sulfate proteoglycans have profound effects at the cellular, tissue, and organismal level.

1 June 2002 in Annual Review of Biochemistry
Verified
Journal Article
Closed access
JEJeffrey D. Esko
Jeffrey D. Esko
SSScott B. Selleck
Scott B. Selleck
▪ Abstract Virtually every cell type in metazoan organisms produces heparan sulfate. These complex polysaccharides provide docking sites for numerous protein ligands and receptors involved in diverse biological processes, including growth control, signal transduction, cell adhesion, hemostasis, and lipid metabolism. The binding sites consist of relatively small tracts of variably sulfated glucosamine and uronic acid residues in specific arrangements. Their formation occurs in a tissue-specific fashion, generated by the action of a large family of enzymes involved in nucleotide sugar metabolism, polymer formation (glycosyltransferases), and chain processing (sulfotransferases and an epimerase). New insights into the specificity and organization of the biosynthetic apparatus have emerged from genetic studies of cultured cells, nematodes, fruit flies, zebrafish, rodents, and humans. This review covers recent developments in the field and provides a resource for investigators interested in the incredible diversity and specificity of this process.

2 June 2014 in Annual Review of Biochemistry
Verified
Journal Article
Closed access
DXDing Xu
Ding Xu
JEJeffrey D. Esko
Jeffrey D. Esko
Numerous proteins, including cytokines and chemokines, enzymes and enzyme inhibitors, extracellular matrix proteins, and membrane receptors, bind heparin. Although they are traditionally classified as heparin-binding proteins, under normal physiological conditions these proteins actually interact with the heparan sulfate chains of one or more membrane or extracellular proteoglycans. Thus, they are more appropriately classified as heparan sulfate–binding proteins (HSBPs). This review provides an overview of the various modes of interaction between heparan sulfate and HSBPs, emphasizing biochemical and structural insights that improve our understanding of the many biological functions of heparan sulfate.

15 July 2001 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
JEJeffrey D. Esko
Jeffrey D. Esko
ULUlf Lindahl
Ulf Lindahl

11 July 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PGPhilip L.S.M. Gordts
Philip L.S.M. Gordts
RNRyan Nock
Ryan Nock
NSNi-Huiping Son
Ni-Huiping Son
BRBastian Ramms
Bastian Ramms
ILIrene Lew
Irene Lew
JEJeffrey D. Esko
Jeffrey D. Esko
Hypertriglyceridemia is an independent risk factor for cardiovascular disease, and plasma triglycerides (TGs) correlate strongly with plasma apolipoprotein C-III (ApoC-III) levels. Antisense oligonucleotides (ASOs) for ApoC-III reduce plasma TGs in primates and mice, but the underlying mechanism of action remains controversial. We determined that a murine-specific ApoC-III–targeting ASO reduces fasting TG levels through a mechanism that is dependent on low-density lipoprotein receptors (LDLRs) and LDLR-related protein 1 (LRP1). ApoC-III ASO treatment lowered plasma TGs in mice lacking lipoprotein lipase (LPL), hepatic heparan sulfate proteoglycan (HSPG) receptors, LDLR, or LRP1 and in animals with combined deletion of the genes encoding HSPG receptors and LDLRs or LRP1. However, the ApoC-III ASO did not lower TG levels in mice lacking both LDLR and LRP1. LDLR and LRP1 were also required for ApoC-III ASO–induced reduction of plasma TGs in mice fed a high-fat diet, in postprandial clearance studies, and when ApoC-III–rich or ApoC-III–depleted lipoproteins were injected into mice. ASO reduction of ApoC-III had no effect on VLDL secretion, heparin-induced TG reduction, or uptake of lipids into heart and skeletal muscle. Our data indicate that ApoC-III inhibits turnover of TG-rich lipoproteins primarily through a hepatic clearance mechanism mediated by the LDLR/LRP1 axis.